We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Molecular Pathway Mimics Androgen Binding in Advanced Prostate Cancer

By LabMedica International staff writers
Posted on 20 Jul 2010
Cancer researchers have identified a molecular pathway that explains how advanced prostate tumors that should require androgens for growth manage to survive and spread despite treatment that isolates them from any sex hormone activity.

The outstanding question is whether there is another mechanism that triggers androgen receptor signaling even when there are no sex hormones present.

To answer this question, investigators at the University of North Carolina (Chapel Hill, USA) examined the interaction between androgen receptor regulated genes in prostate cancer cells and coregulatory proteins that included the melanoma antigen gene protein-A11 (MAGE-11).

They reported in the July 9, 2010, issue of the Journal of Biological Chemistry that MAGE-11 contributed to androgen receptor transcriptional activity through an interaction with a protein called p300, a potent and ubiquitous transcriptional regulator. More...
This interaction depended on binding of MAGE-11 to the NH2-terminal domains of the androgen receptor and of p300.

Senior author Dr. Elizabeth M. Wilson, professor of pediatric biochemistry and biophysics at the University of North Carolina, explained, "We found that a small portion of the androgen receptor interacts with the MAGE-11 molecule which serves as a bridge to p300, a strong histone modifying enzyme that increases androgen receptor activity. This is exciting because it shows how the cancer cells have developed a way to boost androgen receptor activity, even in the absence or at low levels of the hormone that binds the androgen receptor. The MAGE-11 molecule is a promising target for shutting down androgen receptor activity that promotes the growth of cancer cells.”

Related Links:
University of North Carolina




New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The method that profiles DNA methylation in cell-free DNA from a single blood sample to detect disease signals system-wide (photo courtesy of Shutterstock)

cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample

Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.